On Jun. 11, 2020, AIM ImmunoTech announced that it had filed a provisional patent application for, among other discoveries, the use of its experimental drug Ampligenﾮ as a potential early-onset therapy for the treatment of COVID-19 induced chronic fatigue, which showed similarities to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Ampligenﾮ, approved in Argentina, is late-stage in the experimental development pipeline in the U.S.